1-5 of 5
Jeanette Dilley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel

Jane Zhang, Nagarajan Ramesh, Yu Chen, Yuanhao Li, Jeanette Dilley, Peter Working, De-Chao Yu
Journal: Cancer Research
Cancer Res (2002) 62 (13): 3743–3750.
Published: 01 July 2002
View article titled, Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel
Open the PDF for Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel in another window
Journal Articles

CV706, a Prostate Cancer-specific Adenovirus Variant, in Combination with Radiotherapy Produces Synergistic Antitumor Efficacy without Increasing Toxicity

Yu Chen, Theodore DeWeese, Jeanette Dilley, Yiwei Zhang, Yuanhao Li, Nagarajan Ramesh, Jake Lee, Rukmini Pennathur-Das, John Radzyminski, Joseph Wypych, Dominic Brignetti, Sara Scott, Jennifer Stephens, David B. Karpf, Daniel R. Henderson, De-Chao Yu
Journal: Cancer Research
Cancer Res (2001) 61 (14): 5453–5460.
Published: 01 July 2001
View article titled, CV706, a Prostate Cancer-specific Adenovirus Variant, in Combination with Radiotherapy Produces Synergistic Antitumor Efficacy without Increasing Toxicity
Open the PDF for CV706, a Prostate Cancer-specific Adenovirus Variant, in Combination with Radiotherapy Produces Synergistic Antitumor Efficacy without Increasing Toxicity in another window
Journal Articles

Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel

De-Chao Yu, Yu Chen, Jeanette Dilley, Yuanhao Li, Millicent Embry, Hong Zhang, Natalie Nguyen, Pinky Amin, Joe Oh, Daniel R. Henderson
Journal: Cancer Research
Cancer Res (2001) 61 (2): 517–525.
Published: 01 January 2001
View article titled, Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel
Open the PDF for Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel in another window
Journal Articles

The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts

De-Chao Yu, Yu Chen, Monica Seng, Jeanette Dilley, Daniel R. Henderson
Journal: Cancer Research
Cancer Res (1999) 59 (17): 4200–4203.
Published: 01 September 1999
View article titled, The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts
Open the PDF for The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts in another window
Journal Articles

Definition of the High-Risk Acute Lymphoblastic Leukemia Patient by Immunological Phenotyping with Monoclonal Antibodies

Theodore F. Zipf, Robert I. Fox, Jeanette Dilley, Ronald Levy
Journal: Cancer Research
Cancer Res (1981) 41 (11_Part_2): 4786–4789.
Published: 01 November 1981
View article titled, Definition of the High-Risk Acute Lymphoblastic Leukemia Patient by Immunological Phenotyping with Monoclonal Antibodies
Open the PDF for Definition of the High-Risk Acute Lymphoblastic Leukemia Patient by Immunological Phenotyping with Monoclonal Antibodies in another window